Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) FCF Margin (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed FCF Margin for 10 consecutive years, with 320.14% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, FCF Margin rose 22538.0% year-over-year to 320.14%, compared with a TTM value of 83.81% through Sep 2025, up 1421.0%, and an annual FY2024 reading of 86.75%, up 344969.0% over the prior year.
  • FCF Margin was 320.14% for Q3 2025 at Spero Therapeutics, up from 124.7% in the prior quarter.
  • Across five years, FCF Margin topped out at 7300.46% in Q3 2023 and bottomed at 11426.32% in Q1 2022.
  • Average FCF Margin over 5 years is 476.21%, with a median of 176.86% recorded in 2021.
  • The sharpest move saw FCF Margin skyrocketed 5539267bps in 2021, then tumbled -1121427bps in 2022.
  • Year by year, FCF Margin stood at 176.86% in 2021, then soared by 270bps to 301.49% in 2022, then skyrocketed by 257bps to 1077.82% in 2023, then plummeted by -129bps to 311.47% in 2024, then surged by 203bps to 320.14% in 2025.
  • Business Quant data shows FCF Margin for SPRO at 320.14% in Q3 2025, 124.7% in Q2 2025, and 68.13% in Q1 2025.